AIM ImmunoTech Faces Delisting Concerns
Ticker: AIM · Form: 8-K · Filed: Apr 7, 2025 · CIK: 946644
Sentiment: bearish
Topics: delisting, listing-standards, regulatory
TL;DR
AIM ImmunoTech might be delisted - big trouble brewing.
AI Summary
AIM ImmunoTech Inc. filed an 8-K on April 7, 2025, reporting events as of April 4, 2025. The filing indicates a potential notice of delisting or failure to meet continued listing standards, along with other events and financial statements/exhibits. The company was formerly known as Hemispherx Biopharma Inc. before changing its name on June 14, 1995.
Why It Matters
This filing signals potential issues with AIM ImmunoTech's continued listing on an exchange, which could impact its stock trading and investor confidence.
Risk Assessment
Risk Level: high — The filing explicitly mentions 'Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard', indicating significant risk to the company's exchange listing.
Key Players & Entities
- AIM ImmunoTech Inc. (company) — Registrant
- Hemispherx Biopharma Inc. (company) — Former company name
- April 4, 2025 (date) — Date of earliest event reported
- April 7, 2025 (date) — Filing date
- June 14, 1995 (date) — Date of name change
FAQ
What specific listing rule or standard has AIM ImmunoTech Inc. failed to satisfy?
The filing does not specify the exact rule or standard that has not been satisfied, only that a notice of delisting or failure to satisfy one is being reported.
What are the 'Other Events' mentioned in the filing?
The filing does not detail the specific 'Other Events' beyond the notice of potential delisting.
What is the significance of the 'Financial Statements and Exhibits' being filed?
These are typically filed to accompany the reported events and provide supporting financial information or documentation.
What is the company's principal executive office address?
The company's principal executive offices are located at 2117 SW Highway 484, Ocala, FL 34473.
When did the company change its name from Hemispherx Biopharma Inc.?
The company changed its name from Hemispherx Biopharma Inc. on June 14, 1995.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on April 7, 2025 regarding AIM ImmunoTech Inc. (AIM).